Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Peng, DunFa ^a   Hu, Tian Ling ^a   Jiang, Aixiang ^a   Washington, Mary Kay ^a   Moskaluk, Christopher A ^b   Schneider Stock, Regine ^c   El Rifai, Wael ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; GROWTH INHIBITOR; HISTONE; NERVE PROTEIN; REPRESSOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CELL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; GENE; GENE EXPRESSION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; METALLOTHIONEIN 3 GENE; PROMOTER REGION; PYROSEQUENCING; TRANSCRIPTION INITIATION SITE; ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; DRUG EFFECT; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE; TUMOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HISTONES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; REPRESSOR PROTEINS;

EID: 79960462307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022009     Document Type: Article

References (47)

1. Blot WJ, Devesa SS, Fraumeni JF Jr, (1993) Continuing climb in rates of esophageal adenocarcinoma: an update. Jama 270: 1320.
2. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ, (1989) The increasing frequency of adenocarcinoma of the esophagus. Cancer 64: 526-530.
3. DeMeester SR, (2006) Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 13: 12-30.
4. Altorki NK, Skinner DB, (1990) Adenocarcinoma in Barrett's esophagus. Semin Surg Oncol 6: 274-278.
5. Falk GW, (1994) Barrett's esophagus. Gastrointest Endosc Clin N Am 4: 773-789.
6. Fitzgerald RC, (2004) Barrett metaplasia: reassessment of treatment and follow-up. Curr Opin Oncol 16: 372-377.
7. Bonino JA, Sharma P, (2004) Barrett esophagus. Curr Opin Gastroenterol 20: 375-380.
8. Falk GW, (2001) Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 33: 109-118.
9. Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, et al. (1995) Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut 37: 168-173.
10. Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, et al. (2007) Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 56: 763-771.
11. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
12. Esteller M, Corn PG, Baylin SB, Herman JG, (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
13. Lennartsson A, Ekwall K, (2009) Histone modification patterns and epigenetic codes. Biochim Biophys Acta 1790: 863-868.
14. Shukla A, Chaurasia P, Bhaumik SR, (2009) Histone methylation and ubiquitination with their cross-talk and roles in gene expression and stability. Cell Mol Life Sci 66: 1419-1433.
15. Zhou W, Wang X, Rosenfeld MG, (2009) Histone H2A ubiquitination in transcriptional regulation and DNA damage repair. Int J Biochem Cell Biol 41: 12-15.
16. Kondo Y, (2009) Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 50: 455-463.
17. Momparler RL, (2003) Cancer epigenetics. Oncogene 22: 6479-6483.
18. Kagi JH, Hunziker P, (1989) Mammalian metallothionein. Biol Trace Elem Res 21: 111-118.
19. Carpene E, Andreani G, Isani G, (2007) Metallothionein functions and structural characteristics. J Trace Elem Med Biol 21 (Suppl 1): 35-39.
20. Coyle P, Philcox JC, Carey LC, Rofe AM, (2002) Metallothionein: the multipurpose protein. Cell Mol Life Sci 59: 627-647.
21. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE, (2001) Metallothionein III is reduced in Alzheimer's disease. Brain Res 894: 37-45.
22. Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, et al. (2001) Localization, regulation, and function of metallothionein-III/growth inhibitory factor in the brain. Acta Med Okayama 55: 1-9.
23. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, et al. (2000) Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 108: 413-418.
24. Sens MA, Somji S, Garrett SH, Beall CL, Sens DA, (2001) Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159: 21-26.
25. Garrett SH, Sens MA, Shukla D, Nestor S, Somji S, et al. (1999) Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate 41: 196-202.
26. Deng D, El-Rifai W, Ji J, Zhu B, Trampont P, et al. (2003) Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 24: 25-29.
27. Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, et al. (2005) Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 4: 42.
28. You HJ, Oh DH, Choi CY, Lee DG, Hahm KS, et al. (2002) Protective effect of metallothionein-III on DNA damage in response to reactive oxygen species. Biochim Biophys Acta 1573: 33-38.
29. Jeong HG, Youn CK, Cho HJ, Kim SH, Kim MH, et al. (2004) Metallothionein-III prevents gamma-ray-induced 8-oxoguanine accumulation in normal and hOGG1-depleted cells. J Biol Chem 279: 34138-34149.
30. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
31. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP, (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196.
32. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, et al. (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714-717.
33. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466.
34. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, et al. (2006) DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27: 1160-1168.
35. Peng DF, Razvi M, Chen H, Washington K, Roessner A, et al. (2009) DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut 58: 5-15.
36. Kanai Y, Hirohashi S, (2007) Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28: 2434-2442.
37. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB, (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107.
38. Laird PW, (2005) Cancer epigenetics. Hum Mol Genet 14 Spec No 1: R65-76.
39. Pinskaya M, Morillon A, (2009) Histone H3 lysine 4 di-methylation: a novel mark for transcriptional fidelity? Epigenetics 4: 302-306.
40. Wiencke JK, Zheng S, Morrison Z, Yeh RF, (2008) Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 27: 2412-2421.
41. Khalil AM, Driscoll DJ, (2006) Histone H3 lysine 4 dimethylation is enriched on the inactive sex chromosomes in male meiosis but absent on the inactive X in female somatic cells. Cytogenet Genome Res 112: 11-15.
42. Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, et al. (2010) Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst 102: 271-274.
43. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, et al. (2000) The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47: 251-255.
44. Siewert JR, Feith M, Stein HJ, (2005) Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 90: 139-146; discussion 146.
45. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, et al. (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62: 6823-6826.
46. Dasgupta P, Chellappan SP, (2007) Chromatin immunoprecipitation assays: molecular analysis of chromatin modification and gene regulation. Methods Mol Biol 383: 135-152.
47. Reiner A, Yekutieli D, Benjamini Y, (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.